Stoke Therapeutics meets with FDA on Dravet syndrome drug NDA
Tweet Send to a Friend
Stoke Therapeutics (Nasdaq: STOK) announced it has completed a meeting with the U.S. Food and Drug Administration to align on ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




